Tecentriq - direct healthcare professional communication (DHPC)

atezolizumab
DHPCHuman

Finnish is available via eTranslation, the European Commission's machine translation service.

Translate to Finnish | Important information about machine translation

Tietoja

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Asiakirjat

Direct healthcare professional communication (DHPC): Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)

English (EN) (150.16 KB - PDF)

Julkaistu ensimmäisen kerran:
Näytä

Key facts

Medicine name
Tecentriq
Active substance
atezolizumab
Therapeutic area (MeSH)
  • Carcinoma, Transitional Cell
  • Carcinoma, Non-Small-Cell Lung
  • Urologic Neoplasms
  • Breast Neoplasms
  • Small Cell Lung Carcinoma
Procedure number
EMEA/H/C/00414/II/0054
Regulatory outcome
Variation
DHPC type
Adverse event
Human ATC codes
L01FX06
Dissemination date

Share this page